The Sbarro Health Research Organization
Is a nonprofit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism.
SHRO researchers have completed research on new technologies designed to diagnose lung, ovarian, endometrial, breast and brain tumors as well as lymphomas. Their work with gene therapy has also led to new strategies to treat tumors of the lung and brain and has led to over twenty patents.
Pioneering Biomedical Solutions Through Molecular Research
At Sbarro Health Research Organization (SHRO) we specialize in research aimed at finding cures for cancer, cardiovascular and other diseases by identifying their underlying molecular mechanisms.
SHRO is dedicated to supporting scientific research aimed at finding cures for cancer, cardiovascular and other diseases by identifying their underlying molecular mechanisms. SHRO includes the Sbarro Institute for Cancer Research and Molecular Medicine located at Temple University in Philadelphia, PA and an SHRO affiliated laboratory located at the University of Siena in Siena, Italy. Over 200 SHRO molecular biologists, geneticists, physicists, and chemists work to develop new methods to understand, diagnose and cure disease.
SHRO: International Leadership in Cancer and Disease Research
When Professor Giordano started SHRO he wanted to create an organization that would focus on biomedical research. It was also very important to Dr. Antonio Giordano that SHRO remains autonomous in terms of academics and funding so SHRO is solely funded through private grants and donations. Mario Sbarro took a leap of faith in 1993 by providing funding to Sbarro Institute to get started. Mr. Sbarro remains a valuable part of our organization to this day.
When Dr. Giordano moved to Temple University in 2002, he and twenty fellow scientists forged a new, three-year alliance with Temple University in Philadelphia, Pennsylvania. Under the new arrangement, the original Sbarro Institute was renamed the Sbarro Health Research Organization, Inc. (SHRO), which includes the Sbarro Institute for Cancer Research and Molecular Medicine at Temple and the SHRO-affiliated laboratory at the University of Siena in Siena, Italy.
Under a 2005 agreement, the Sbarro Institute for Cancer Research and Molecular Medicine received continued funding from Temple and expanded its program to include work on the relationship between obesity and cancer and instituted a new program on molecular therapeutics to explore how molecular genetic research can be applied to patient therapies and diagnostics.
In April 2013, the Sbarro Institute ranks second in number of publications (as many as 22o) as reported in the Cell Cycle registry.